Androsta-1,4-dien-3-one,17-hydroxy-17-methyl-, (17b)- With the CAS registry number 72-63-9, is white to off-white crystalline powder. its product Name is Metandienone. it is an orally-effective anabolic steroid originally developed in Germany and released in the US in the early 1960s by Ciba Specialty Chemicals.
1. Chemical Properties
Name:Androsta-1,4-dien-3-one,17-hydroxy-17-methyl-, (17b)-
EINECS:200-787-2
Molecular Formula:C20H28O2
CAS Registry Number:72-63-9
InChI:InChI=1/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1
HS Code:29329970
Appearance:white to off-white crystalline powder
Molecular Weight:300.44
Density:1.12 g/cm3
Boiling Point:436.5 °C at 760 mmHg
Melting Point:163 – 167 C
Flash Point:436.5 °C at 760 mmHg
Storage Temperature:2-8°C
Refractive index:1.572
Solubility:practically insoluble <
Usage:Anabolic steroid. Androgen. Controlled substance.
2. Safety Information
RIDADR: 3249
WGK Germany : 3
RTECS: BV8000000
F: 8
HazardClass: 6.1(b)
PackingGroup: III
HS Code: 29329970
Hazardous Substances Data: 72-63-9
Methyl methacrylate is a colourless liquid compound, used in the manufacture of certain methacrylate resins and plastics. Methyl methacrylate is irritating to the skin, eyes, and mucous membranes in humans. An allergic response to dermal exposure may develop. Respiratory effects have been reported in humans following acute (short-term) and chronic (long-term) inhalation exposures. Respiratory symptoms observed following acute exposures include chest tightness, dyspnea, coughing, wheezing, and reduced peak flow. Neurological symptoms have also been reported in humans following acute exposure to methyl methacrylate. Fetal abnormalities have been reported in animals exposed to methyl methacrylate by injection and inhalation. EPA considers methyl methacrylate not likely to be carcinogenic to humans.
1. Acute Effects
*Methyl methacrylate(CAS.NO:80-62-6) is irritating to the skin, eyes, and mucous membranes in humans. An allergic response to dermal exposure may develop.
*Respiratory symptoms reported in humans include chest tightness, dyspnea, coughing, wheezing, and reduced peak flow.
*Neurological symptoms, including headache, lethargy, lightheadedness, and sensation of heaviness in arms and legs, have occurred in humans following acute exposure to methyl methacrylate.
*In mice and rats acutely exposed to high concentrations of methyl methacrylate by inhalation, degenerative olfactory changes in the nasal passages and lung damage have been observed. High doses of methyl methacrylate may cause pulmonary edema.
*Acute oral exposure of animals to methyl methacrylate has caused damage to the liver.
*Tests involving acute exposure of rats, mice, rabbits, and guinea pigs have demonstrated methyl methacrylate to have low to moderate acute toxicity by inhalation or oral exposure.
2. Chronic Effects (Noncancer)
*Respiratory and nasal symptoms and reduced lung function have been reported in chronically exposed workers.
*In one study, occupational exposure to high doses of methyl methacrylate was associated with cardiovascular disorders in humans.
*Chronic inhalation of methyl methacrylate by rats has resulted in respiratory effects (e.g., inflammation of the nasal cavity, degeneration/loss of olfactory epithelium in nasal turbinates, and lung congestion). Chronic inhalation of high levels of methyl methacrylate has resulted in degenerative and necrotic changes in the liver, kidney, brain, spleen, and bone marrow, decreased body weight gain, listlessness, prostration, and ocular and nasal discharge in animals.
*EPA has calculated a Reference Concentration (RfC) for methyl methacrylate of 0.7 milligrams per cubic meter (mg/m3) based on respiratory effects in rats. The RfC is an estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely to be without appreciable risk of deleterious noncancer effects during a lifetime. It is not a direct estimator of risk but rather a reference point to gauge the potential effects. At exposures increasingly greater than the RfC, the potential for adverse health effects increases. Lifetime exposure above the RfC does not imply that an adverse health effect would necessarily occur.
*EPA has medium to high confidence in the RfC based on:
(1) high confidence in the principal study because it was a long-term inhalation study performed with large group sizes, with additional histopathological analyses, described effects to the target organ well, and identified a no observed adverse effect level (NOAEL) and lowest observed adverse effect level (LOAEL);
(2) medium to high confidence in the database because developmental studies were performed in two species, with effects observed only in offspring at levels more than 10-fold higher than the LOAEL for the critical effect, and no multigenerational reproductive studies are available.
*EPA has calculated a Reference Dose (RfD) of 1.4 milligrams per kilogram body weight per day (mg/kg/d) based on no adverse effects in rats.
*EPA has low to medium confidence in the RfD based on: (1) low to medium confidence in the principal study because it was not conducted in accordance with Good Laboratory Practice and did not identify a LOAEL, and (2) low to medium confidence in the database because quantitative human subchronic or chronic studies are not available and although repeat exposure inhalation studies (including developmental, reproductive, and chronic studies) bolster the weak and dated oral database somewhat, no developmental or reproductive studies by the oral route are available and no multigenerational studies are available by any route of exposure.
3. Reproductive/Developmental Effects
*No adequate reproductive or developmental studies in humans are available.
*Inhalation exposure of rats to maternally-toxic levels of methyl methacrylate resulted in fetal abnormalities (hematomas and skeletal anomalies) and decreased fetal weight and crown-rump length.
4. Cancer Risk
*From a retrospective epidemiology study, a causal relationship between occupational exposure and increased incidences of colon and rectal cancers has been suggested; however, the causal relationship could not be established when relative accumulated total exposures and latency were considered.
*No carcinogenic effects were observed in several inhalation and oral animal studies.
*EPA considers methyl methacrylate not likely to be carcinogenic to humans.
Arbutin is a naturally occuring derivative of hydroquinone found in the leaves of cranberry, bearberry, and blueberry shrubs, most types of pears, and many other plants. Arbutin may inhibit melanogenesis by affecting tyrosinase activity.
1. Mechanism of action of arbutin
The mechanism of action of arbutin is through the competitive inhibition of the enzyme tyrosinase, a key enzyme in the synthesis of melanin, although it has been suggested that it may also affect other steps in the synthesis and accumulation of melanin.
2. Application
1). Arbutin used in cosmetic industry:
Arbutin protect the skin against damage caused by free radicals, Arbutin is a skin whitening agent which is very popular in Japan and Asian countries for skin de-pigmentation, Arbutin inhibits the formation of melanin pigment by inhibiting Tyrosinase activity.
Arbutin is very safe skin agent for external use which does not have toxicity, stimulation, unpleasant odor or side effect such as Hydroqinone.The encapsulation of Arbutin constitute a delivery system to potentialize the effect in time. It is a way to incorporate the hydrophilic Arbutin in lipophilic media. Arbutin give three main properties; Whitening effects, anti- age effect and UVB/ UVC filter .
Bearberry extract is used in skin lightening treatments designed for long term and regular use. An active agent in brands of skin lightening preparations, it is more expensive than traditional skin lightening ingredients like hydroquinone, which is now banned in many countries. In vitro studies of human melanocytes exposed to arbutin at concentrations below 300 μg/mL reported decreased tyrosinase activity and melanin content with little evidence of cytotoxicity.
2). Arbutin in medical use:
Back in the 18th century, Arbutin was first used in medical areas as an anti-inflammatory and antibacterial agent. Arbutin was used particularly for cystitis, urethritis and pyelitis. These uses still until today where natural medicine uses only natural ingredients to treat any disease.
Also arbutin may be used to repress the virulence of bacterial pathogens and to prevent contaminating bacteria, it is also used for treating allergic inflammation of the skin . More recently, Arbutin has been used to prevent pigmentation and to whiten the skin beautifully. In the meanwhile, arbutin can be used to whiten the skin, to prevent liver spots and freckles, to treat sunburn marks and to regulate melanogenesis.
3. Production
Pure arbutin can be prepared synthetically from the reaction of acetobromoglucose and hydroquinone in the presence of alkali.
4. Indications
Arbutin pure Active is indicated for treating hyperpigmented areas and dark spots. It is well known for reducing melanin levels, whitening the skin and the marks caused by sunburn.
5. Action
By inhibiting the production of melanin, the pigment responsible for the colouring of the skin, Arbutin lightens the skin, reduces the intensity of dark spots and evens out the complexion. Indeed, it has depigmentation properties to lighten the skin.
6. Risks
Arbutin is glucosylated hydroquinone,and may carry similar cancer risks, although there are also claims that arbutin reduces cancer risk. The German Institute of Food Research in Potsdam found that intestinal bacteria can transform arbutin into hydroquinone, which creates an environment favorable for intestinal cancer.